Physician profile
Charles D Williamson
NPI 1699737205
$1,414.15
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $276 · 2021: $464 · 2022: $463.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $464.64 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $310.01 | 2019-2022 | |
| Allergan, INC. | $283.64 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $142.17 | 2019-2022 | |
| Abbvie INC. | $104.25 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $29.04 | 2019 | |
| Biotissue Holdings INC. | $28.56 | 2021-2022 | |
| Shire North American Group INC | $20.57 | 2019 | |
| Alcon Vision LLC | $16.95 | 2022 | |
| Oyster Point Pharma, INC. | $14.32 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Williamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.